ClinicalTrials.gg
RecruitingNCT05640635ECMOWeanUpdated Jun 24, 2024

Inflammation During ECMO Therapy and ECMO Weaning

An interventional study of Ventilator weaning first and ECMO weaning first in Acute Respiratory Distress Syndrome, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Respiratory Distress Syndrome with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Respiratory Distress Syndrome · Germany.

Planned enrollment
19th of 26
40 · median 114
Started
2023
with 1 other
No phase
13 of 48
3 open now
Registered
45th of 48
by date
Lead sponsor
7 of 48
University Hospital Tuebingen

Among the 48 studies in Respiratory Distress Syndrome with a site in Germany, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 45th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

7 of the 48 studies in Respiratory Distress Syndrome with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Respiratory Distress Syndrome with a site in Germany, or all of them as a file.
02

Study summary

The goal of this interventional clinical trial is to compare patients who undergo ECMO therapy for treatment of acute respiratory distress syndrome (ARDS) and a randomized into one of two possible weaning strategy groups.

Group 1: Weaning from ventilator occurs before ECMO weaning.

Group 2: Weaning from ECMO occurs before weaning from ventilator.

This study investigates which one of these strategies is more indulgent for the lung, and leads to less inflammation and therefore less potential side effects and an overall more favourable clinical course.

As a primary criterion, measure of IL-6 in blood samples will beused. As secondary criterions, SOFA score at various time points, ventilation pressures, lung injury score (LIS), length of stay in the intensive care unit, and ventilator-associated pneumonia as well as levels of inflammatory cells and cytokines in both blood samples and bronchoalveolar lavage at different time points will be determined.

03

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • Acute Respiratory Distress Syndrome
  • Extracorporal membrane oxygenation
  • Extracorporal membrane oxygenation weaning
  • Ventilation therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute respiratory distress syndrome (ARDS) according to the Berlin Definition (PaO2/FiO2 \< 100) and treatment with veno-venous ECMO (vvECMO)
  • Hemodynamic stability
  • Lung compliance did not change/improved during the last 24 hours
  • Tidal volume did not change/improved during the last 24 hours with a PEEP of 10 cmH20 or above
  • Consent of the patient or their legal representative

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Artificial ventilation for more than 7 days prior
  • Patient, legal representative or doctors decided against an unrestricted intensive care treatment
  • Positive pregnancy test at time of screening
  • Cardiac failure requiring veno-arterial ECMO therapy
  • Chronic respiratory insufficiency requiring long-term oxygen treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Ventilator weaning first

    Procedure: Ventilator weaning first

  • Active comparator
    ECMO weaning first

    Procedure: ECMO weaning first

Interventions

  • ProcedureVentilator weaning first

    Ventilator weaning initiated and completed before start of ECMO weaning.

  • ProcedureECMO weaning first

    ECMO weaning initiated and completed before start of ventilator weaning.

06

What researchers measure

Primary outcomes

  1. IL-6 concentration (blood samples)

    Daily control of above mentioned parameter.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

Secondary outcomes

  1. SOFA-Score

    Sequential organ failure assessement score evaluated at days 1-14, 28, and 60.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days at indicated time points as described above..

  2. Ventilation pressures

    Pressures applied to the lung during artificial ventilation

    Time frame: For the duration of the artificial ventilation, or a maximum of 60 days.

  3. Murray Lung Injury Score (LIS)

    Assessement of severity of lung damage by the established Lung Injury Score by Murray (Min Value is 0, healthy and Max Value is 20, severly diseased)

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

  4. Length of stay in the intensive care unit

    Length of stay in the intensive care unit.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

  5. Ventilator-associated pneumonia

    Occurence/incidence of ventilator-associated pneumonia.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

  6. Cytokines and inflammatory cells in blood samples (IL-1beta, Il-10 and TNF-alpha)

    Collection of blood samples at various times points for further analysis.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

  7. Cytokines and inflammatory cells in bronchoalveolar lavage (IL-1beta, Il-10 and TNF-alpha)

    Collection of bronchoalveolar lavage samples at various times points for further analysis.

    Time frame: For the duration of the ICU stay, or a maximum of 60 days.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2026, 36 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Dec 7, 2022
StartActual
Jan 1, 2023
Primary completionEst.
Jan 2026
CompletionEst.
Dec 2026
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05640635
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Jan 1, 2023
Primary completion
Jan 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 24, 2024

Study contacts

Peter Rosenberger, Prof.
Contact
peter.rosenberger@med.uni-tuebingen.de
+49707129 ext. 86622
Peter Rosenberger, Prof.
principal investigator · University Hospital Tuebingen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion